Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1712-1720

  Doolittle, Nancy D ^a   Jahnke, Kristoph ^a   Belanger, Richard ^b   Ryan, Deborah A ^b   Nance Jr , Robert W ^c   Lacy, Cynthia A ^a   Tyson, Rose Marie ^a   Haluska, Marianne ^a   Hedrick, Nancy A ^a   Varallyay, Csanad ^a   Neuwelt, Edward A ^a,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Ryan Belanger Associates   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Primary central nervous system lymphoma; Radioimmunotherapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOFOS; ETOPOSIDE; GADOLINIUM; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; SODIUM THIOSULFATE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSIMETRY; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; THROMBOCYTOPATHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 34548573093     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701493902     Document Type: Article

References (41)

1. CBTRUS (2005) Primary brain tumors in the United States, 1998 - 2002, Central Brain Tumor Registry of the United States, Chicago, IL
2. Abrey, L. E., DeAngelis, L. M. and Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol, 16, pp. 859-863.
3. Batchelor, T. and Loeffler, J. S. (2006) Primary CNS lymphoma. J Clin Oncol, 24, pp. 1281-1288.
4. DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B. and Schultz, C. J. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93 - 10. J Clin Oncol, 20, pp. 4643-4648.
5. Lai, R., Rosenblum, M. K. and DeAngelis, L. M. (2002) Primary CNS lymphoma: A whole-brain disease?. Neurology, 59, pp. 1557-1562.
6. McAllister, L. D., Doolittle, N. D., Guastadisegni, P. E., Kraemer, D. F., Lacy, C. A. and Crossen, J. R. (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46, pp. 51-60.
7. Poortmans, P. M., Kluin-Nelemans, H. C., Haaxma-Reiche, H., Veer, M Van't, Hansen, M. and Soubeyran, P. (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol, 21, pp. 4483-4488.
8. Ervin, T. and Canellos, G. P. (1980) Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer, 45, pp. 1556-1557.
9. Reni, M. and Ferreri, A. J. (2001) Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol, 80, pp. B113-B117.
10. Nguyen, P. L., Chakravarti, A., Finkelstein, D. M., Hochberg, F. H., Batchelor, T. T. and Loeffler, J. S. (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol, 23, pp. 1507-1513.
11. Plotkin, S. R., Betensky, R. A., Hochberg, F. H., Grossman, S. A., Lesser, G. J. and Nabors, L. B. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res, 10, pp. 5643-5646.
12. Reni, M., Mason, W., Zaja, F., Perry, J., Franceschi, E. and Bernardi, D. (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer, 40, pp. 1682-1688.
13. Voloschin, A. D., Wen, P., Hochberg, F. and Batchelor, T. (2004) Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final report. Neurology, 62, p. 478.
14. Fischer, L., Thiel, E., Klasen, H. A., Birkmann, J., Jahnke, K. and Martus, P. (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol, 17, pp. 1141-1145.
15. Herrlinger, U., Brugger, W., Bamberg, M., Kuker, W., Dichgans, J. and Weller, M. (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology, 54, pp. 1707-1708.
16. Arellano-Rodrigo, E., Lopez-Guillermo, A., Bessell, E. M., Nomdedeu, B., Montserrat, E. and Graus, F. (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol, 70, pp. 219-224.
17. Khalfallah, S., Stamatoullas, A., Fruchart, C., Proust, F., Delangre, T. and Tilly, H. (1996) Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant, 18, pp. 1021-1023.
18. Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V. and Azar, N. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol, 19, pp. 742-749.
19. Giglio, A del, Costa, L. J., Pinczowski, H., Varella, P. C., Luzzi, J. R. and Neves, P. (1999) Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients. Acta Haematol, 102, pp. 56-58.
20. Tyson, R. M., Siegal, T., Doolittle, N. D., Lacy, C., Kraemer, D. F. and Neuwelt, E. A. (2003) Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma, 44, pp. 627-633.
21. Schulz, H., Pels, H., Schmidt-Wolf, I., Zeelen, U., Germing, U. and Engert, A. (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica, 89, pp. 753-754.
22. Wong, E. T., Tishler, R., Barron, L. and Wu, J. K. (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 101, pp. 139-145.
23. Enting, R. H., Demopoulos, A., DeAngelis, L. M. and Abrey, L. E. (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology, 63, pp. 901-903.
24. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R. and Ferme, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
25. Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. and Klasa, R. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, pp. 5027-5033.
26. Pels, H., Schulz, H., Manzke, O., Hom, E., Thall, A. and Engert, A. (2002) Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol, 59, pp. 213-216.
27. Rubenstein, J. L., Combs, D., Rosenberg, J., Levy, A., McDermott, M. and Damon, L. (2003) Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood, 101, pp. 466-468.
28. Rubenstein, J. L., Rosenberg, J. and Damon, L. E. (1999) High dose methotrexate plus rituximab (anti-CD-20) monoclonal antibody in the treatment of primary CNS lymphoma. Neuro-oncology, 1, p. 336.
29. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. and Joyce, R. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 2453-2463.
30. Press, O. W. and Rasey, J. (2000) Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol, 27, pp. 62-73.
31. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S. and Saleh, M. N. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
32. Doolittle, N. D., Jahnke, K., Belanger, R., Nance, R WJ, Lacy, C. and Tyson, R. M. (2006) Enhanced delivery to the central nervous system of monoclonal antibody based therapy in relapsed primary central nervous system lymphoma. Neurooncology, 8, p. 180.
33. Neuwelt, E. A. and Dahlborg, S. A. (1989) Blood-brain barrier disruption in the treatment of brain tumors: Clinical implications. Implications of the Blood-Brain Barrier and Its Manipulation: Clinical Aspects, pp. 195-262. Plenum, New York
34. Doolittle, N. D., Muldoon, L. L., Brummett, R. E., Tyson, R. M., Lacy, C. and Bubalo, J. S. (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res, 7, pp. 493-500.
35. Neuwelt, E. A., Brummett, R. E., Doolittle, N. D., Muldoon, L. L., Kroll, R. A. and Pagel, M. A. (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther, 286, pp. 77-84.
36. Smith, J. R., Rosenbaum, J. T., Wilson, D. J., Doolittle, N. D., Siegal, T. and Neuwelt, E. A. (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology, 109, pp. 1709-1716.
37. Macdonald, D. R., Cascino, T. L., Schold Jr, S. C. and Cairncross, J. G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8, pp. 1277-1280.
38. Muldoon, L. L. and Neuwelt, E. A. (2003) BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol, 65, pp. 49-62.
39. Stemmler, J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N. and Heinemann, V. (2006) Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol, 24, p. 64S.
40. Neuwelt, E. A., Thrun, L. A., Walker-Rosenfeld, S., Cave, A. T. and Muldoon, L. L. (2003) Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats. Neurosurgery, 53, pp. 1406-1412.
41. Remsen, L. G., Trail, P. A., Hellstrom, I., Hellstrom, K. E. and Neuwelt, E. A. (2000) Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery, 46, pp. 704-709.